TNFRSF17 and plasma cell myeloma: Finally, encouraging preclinical data recently have appeared that portends the possibility of engineering CARs that employ T-cell alternatives, such as NK cells [170,171], to generate novel systems targeting BCMA for future allogeneic product development in the quest for innovative anti-myeloma treatments.